Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients:: One year follow-up study

被引：32

作者：

Falcó, V

Jordano, Q

Cruz, MJ

Len, O

Ribera, E

Campins, M

Crespo, M

Ocaña, I

Rodrigo, MJ

Pahissa, A

机构：

[1] Univ Autonoma Barcelona, Hosp Vall Hebron, Dept Infect Dis, E-08193 Barcelona, Spain

[2] Univ Autonoma Barcelona, Hosp Vall Hebron, Immunol Unit, Dept Biochem, E-08193 Barcelona, Spain

[3] Univ Autonoma Barcelona, Hosp Vall Hebron, Dept Prevent Med, E-08193 Barcelona, Spain

来源：

VACCINE | 2006年 / 24卷 / 14期

关键词：

pneumococcal polysaccharide vaccine; HIV infection;

D O I：

10.1016/j.vaccine.2005.12.021

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The aim of this study was to evaluate specific IgG responses against pneumococcal serotypes 1, 6B, 14, 19F, 23F at baseline, I and 12 months after vaccination with the 23-valent polysaccharide pneumococcal vaccine in 89 HAART-treated HIV-infected patients, 24 antiretroviral "naive" HIV-infected and 30 non-HIV-infected healthy subjects. Levels of specific antipneumococcal IgG and the mean fold increase in IgG levels at I month as well as the kinetics of antibodies along the 12 months in all groups of HIV-infected patients and healthy subjects were similar. Neither CD4 cell count at baseline nor "nadir" CD4 cells correlated with the response to the vaccine. In conclusion, the immunogenicity conferred by the polysaccharide vaccine in HIV-infected patients under HAART is at least as good as that observed in healthy subjects. (c) 2005 Elsevier Ltd. All rights reserved.

引用

收藏

页码：2567 / 2574

页数：8

相关论文

共 36 条

[1] Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial [J].

Ahmed, F ;

Steinhoff, MC ;

RodriguezBarradas, MC ;

Hamilton, RG ;

Musher, DM ;

Nelson, KE .

JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :83-90

[2] Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users [J].

Amendola, A ;

Tanzi, E ;

Zappa, A ;

Colzani, D ;

Boschini, A ;

Musher, DM ;

Zanetti, AR .

VACCINE, 2002, 20 (31-32) :3720-3724

[3] Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens [J].

Atzori, C ;

Clerici, M ;

Trabattoni, D ;

Fantoni, G ;

Valerio, A ;

Tronconi, E ;

Cargnel, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (02) :276-281

[4] Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients [J].

Breiman, RF ;

Keller, DW ;

Phelan, MA ;

Sniadack, DH ;

Stephens, DS ;

Rimland, D ;

Farley, MM ;

Schuchat, A ;

Reingold, AL .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) :2633-2638

[5] ANTIBODY CLASS AND SUBCLASS RESPONSES TO PNEUMOCOCCAL POLYSACCHARIDES FOLLOWING IMMUNIZATION OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS [J].

CARSON, PJ ;

SCHUT, RL ;

SIMPSON, ML ;

OBRIEN, J ;

JANOFF, EN .

JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (02) :340-345

[6] Pneumococcal disease among human immunodeficiency virus-infected persons: Incidence, risk factors, and impact of vaccination [J].

Dworkin, MS ;

Ward, JW ;

Hanson, DL ;

Jones, JL ;

Kaplan, JE .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) :794-800

[7] Serum concentrations of pneumococcal anticapsular antibodies in children with pneumonia associated with Streptococcus pneumonia infection [J].

Esposito, S ;

Droghetti, R ;

Faelli, N ;

Lastrico, A ;

Tagliabue, C ;

Cesati, L ;

Bianchi, C ;

Principi, N .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :1261-1264

[8] Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus-infected adults [J].

Feikin, DR ;

Elie, CM ;

Goetz, MB ;

Lennox, JL ;

Carlone, GM ;

Romero-Steiner, S ;

Holder, PF ;

O'Brien, WA ;

Whitney, CG ;

Butler, JC ;

Breiman, RF .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (01) :137-141

[9] A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults [J].

French, N ;

Moore, M ;

Haikala, R ;

Käyhty, H ;

Gilks, CF .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (04) :707-712

[10] 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial [J].

French, N ;

Nakiyingi, J ;

Carpenter, LM ;

Lugada, E ;

Watera, C ;

Moi, K ;

Moore, M ;

Antvelink, D ;

Mulder, D ;

Janoff, EN ;

Whitworth, J ;

Gilks, CF .

LANCET, 2000, 355 (9221) :2106-2111

← 1 2 3 4 →